$1.12
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 93 full-time employees. The firm is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Country

US

CEO

Mr. Patrick Mercer

IPO date

1996

Employees

93

ISIN

US4626841013

Key stats

Open

$1.12

Volume

29.57K

Market cap

$19.50M

Prev. close

$1.12

Impl / hst vl

-

Open interest

$0.00

$1.10

Day’s Range

$1.12

$0.95

52W Range

$1.65

Valuation

50
Valuation score
Fairly Valued
P/E
-
P/S
0.37
P/B
4.12
Current ratio
1.92
Debt / Equity
-0.18
ROE
-64.23%
Gross margin
40.18%
Income growth
184.78%
FCF growth
-397.31

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.81
The top 3 analysts forecasts that 12-month price may increase by 150.45%, with a low of $2.78 and a high of $2.89
$2.78
Low
$2.81
Avg
$2.89
High
Current price

Earnings

Q2 ‘26 revenue
$11.80M
Q2 ‘26 net income
-$524.00K
Revenue
Net income
Previous EPS
-$0.03
Estimate EPS
-$0.01
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply